• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Antitumor Agents (Enzyme Inhibitors)
You are here: Product Lines > Cancer > Antitumor Reagents > Antitumor Agents (Enzyme Inhibitors)
Toolbar - View Selection
 
Items 44 of 44
ALX-380-091 Revised 21-Aug-08
17-AAG
Add to Clipboard
SYNONYMS 17-(Allylamino)-17-desmethoxygeldanamycin
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antitumor Antibiotics
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-091-C100   100 µg 65.00 USD Add To Cart
ALX-380-091-M001   1 mg 162.00 USD Add To Cart
Product Specification
FORMULA: C31H43N3O8
MW: 585.7
CAS NUMBER: 75747-14-7
SOURCE/HOST: Semisynthetic derivative from geldanamycin.
PURITY: ≥97%
APPEARANCE: Red to dark red powder.
SOLUBILITY: Soluble in DMSO (10mg/ml) or methanol (10mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.

Product Description
Potent, less toxic derivative of geldanamycin (Prod. No. ALX-380-054). Inhibits the essential ATPase activity of HSP90. Inhibitor of telomerase activity. Inducer of apoptosis with antitumor activity.
Product Specific Literature References
Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives: R.C. Schnur, et al.; J. Med. Chem. 38, 3806 (1995) Abstract
The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin: T.W. Schulte & L.M. Neckers; Cancer Chemother. Pharmacol. 42, 273 (1998) Abstract
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone: P.A. Clarke, et al.; Oncogene 19, 4125 (2000) Abstract
Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts: R. Nimmanapalli, et al.; Cancer Res. 61, 1799 (2001) Abstract; Full Text
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells: P.N. Munster, et al.; Cancer Res. 61, 2945 (2001) Abstract; Full Text
Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin: J. Yang, et al.; Cancer Res. 61, 4010 (2001) Abstract; Full Text
Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis: D.M. Nguyen, et al.; Ann. Thorac. Surg. 72, 371 (2001) Abstract
ErbB2 degradation mediated by the co-chaperone protein CHIP: P. Zhou, et al.; J. Biol. Chem. 278, 13829 (2003) Abstract
Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells: R. Villa, et al.; Carcinogenesis 24, 851 (2003) Abstract
Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction: I.A. Vasilevskaya, et al.; Cancer Res. 63, 3241 (2003) Abstract
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors: A. Kamal, et al.; Nature 425, 407 (2003) Abstract
Chaperoning oncogenes: HSP90 as a target of geldanamycin: L. Neckers; Handb. Exp. Pharmacol. 259 (2006) Abstract
Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress: P. Workman, et al.; Ann. N.Y. Acad. Sci. 1113, 202 (2007) Abstract
Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51: Q. Yao, et al.; Clin. Cancer Res. 13, 1591 (2007) Abstract; Full Text
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers: R.K. Ramanathan, et al.; Clin. Cancer Res. 13, 1769 (2007) Abstract
HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells: P.N. Meyer, et al.; Leuk. Res. 32, 143 (2008) Abstract
Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model: C.R. Williams, et al.; J. Urol. 178, 1528 (2007) Abstract
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia: A.J. Johnson, et al.; Br. J. Haematol. 139, 837 (2007) Abstract
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models: U. Banerji, et al.; Cancer Chemother. Pharmacol. 62, 769 (2008) Abstract
Further Categories Containing This Product:
Antibiotics - Apoptosis Inducers & Inhibitors • Antitumor Agents (Enzyme Inhibitors) • Tyrosine Kinase Inhibitors • Antibiotics - Other Signal Transduction Pathway Modulators • HSP90/HtpG/Related Products
 
 
ALX-260-128 Revised 03-Apr-08
Actinonin
Add to Clipboard
SYNONYMS 3[[1-[[2-(Hydroxymethyl)-1-pyrrolidinyl]-carbonyl]-2-methylpropyl]-carbamoyl]-octanohydroxamic acid
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antitumor Antibiotics
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-260-128-M005   5 mg 90.00 USD Add To Cart
Product Specification
FORMULA: C19H35N3O5
MW: 385.5
CAS NUMBER: 13434-13-4
SOURCE/HOST: Synthetic.
PURITY: ≥98%
APPEARANCE: White powder.
SOLUBILITY: Soluble in 100% ethanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Inhibitor of aminopeptidase M, leucine aminopeptidase and deformylase. Shows antitumor activity. Apoptosis inducer.
Product Specific Literature References
Production of actinonin, an inhibitor of aminopeptidase M, by actinomycetes: H. Umezawa, et al.; J. Antibiot. (Tokyo) 38, 1629 (1985) Abstract
Analgesic effect of actinonin, a new potent inhibitor of multiple enkephalin degrading enzymes: M. Hachisu, et al.; Life Sci. 41, 235 (1987) Abstract
Effects of an antibiotic protease inhibitor, actinonin on the growth within collagen gels of non-metastatic and metastatic mouse mammary tumors of the same origin: K. Sayama, et al.; Cancer Lett 94, 171 (1995) Abstract
Inhibition of alanyl aminopeptidase induces MAP-kinase p42/ERK2 in the human T cell line KARPAS-299: U. Lendeckel, et al.; BBRC 252, 5 (1998) Abstract
Antitumor activity of actinonin in vitro and in vivo: Y. Xu, et al.; Clin. Cancer Res. 4, 171 (1998) Abstract
Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor: D.Z. Chen, et al.; Biochemistry 39, 1256 (2000) Abstract
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics: M.D. Lee, et al.; J. Clin. Invest. 114, 1107 (2004) Abstract
Actinonin induces apoptosis in U937 leukemia cells: M. Grujic, et al.; Cancer Lett. 223, 211 (2005) Abstract
Further Categories Containing This Product:
Aminopeptidases/Related Products • Natural Products - Apoptosis Inducers & Inhibitors • Antitumor Agents (Enzyme Inhibitors)
 
 
ALX-385-008 Revised 13-Mar-08
Apigenin
Add to Clipboard
SYNONYMS 4',5,7-Trihydroxyflavone
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Flavonoids/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-385-008-M010   10 mg 35.00 USD Add To Cart
ALX-385-008-M050   50 mg 105.00 USD Add To Cart
Product Specification
FORMULA: C15H10O5
MW: 270.2
CAS NUMBER: 520-36-5
MERCK INDEX: 14: 730
SOURCE/HOST: Synthetic.
PURITY: ≥90% (HPLC)
APPEARANCE: Light yellow to slightly brown powder.
SOLUBILITY: Soluble in diluted potassium hydroxide or DMSO; slightly soluble in 100% ethanol (hot). Insoluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HAZARD: IRRITANT.

Product Description
Antioxidant flavonoid. Has chemopreventive and antitumor properties. Induces apoptosis. Inhibits the proliferation of malignant tumor cells by G2/M arrest. MAP kinase (MAPK/ERK) inhibitor. Inhibits hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) expression.
Product Specific Literature References
Apigenin and tangeretin enhance gap junctional intercellular communication in rat liver epithelial cells: C. Chaumontet, et al.; Carcinogenesis 15, 2325 (1994) Abstract
Apigenin induces morphological differentiation and G2-M arrest in rat neuronal cells: F. Sato, et al.; BBRC 204, 578 (1994) Abstract
Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes: M.L. Kuo and N.C. Yang; BBRC 212, 767 (1995) Abstract
Structure-antioxidant activity relationships of flavonoids and phenolic acids: C.A. Rice-Evans, et al.; Free Radical Biol. & Med. 20, 933 (1996), (Review) Abstract
Apigenin inhibits endothelial-cell proliferation in G(2)/M phase whereas it stimulates smooth-muscle cells by inhibiting P21 and P27 expression: V. Trochon, et al.; Int. J. Cancer 85, 691 (2000) Abstract
Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma: R. Torkin, et al.; Mol. Cancer Ther. 4, 1 (2005) Abstract
Apigenin and cancer chemoprevention: progress, potential and promise: D. Patel, et al.; Int. J. Oncol. 30, 233 (2007), (Review) Abstract
Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression: J. Fang, et al.; Carcinogenesis 28, 858 (2007) Abstract
Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells: S. Shukla & S. Gupta; Cell Cycle 6, 1102 (2007) Abstract
Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation: C. Nicholas, et al.; J. Immunol. 179, 7121 (2007) Abstract
Further Categories Containing This Product:
MAPK Pathway Inhibitors • Antitumor Agents (Enzyme Inhibitors) • Natural Products for Angiogenesis Research • Hypoxia-inducible Factor [HIF]/Related Products • Natural Products - Protein Kinase Inhibitors • Natural Products - Apoptosis Inducers & Inhibitors • Antitumor Agents (Anti-proliferative) • Natural Products - Antitumor Reagents • Natural Products - Antioxidants
 
 
ALX-260-012 Revised 14-Aug-08
Bestatin . hydrochloride
Add to Clipboard
SYNONYMS [(2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoyl]-L-leucine . HCl
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Aminopeptidases/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-260-012-M005   5 mg 55.00 USD Add To Cart
ALX-260-012-M025   25 mg 200.00 USD Add To Cart
Product Specification
FORMULA: C16H24N2O4. HCl
MW: 308.4 . 36.5
CAS NUMBER: 65391-42-6
SOURCE/HOST: Synthetic.
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in methanol, acetic acid, DMSO, dimethyl formamide or 100% ethanol; slightly soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stock solutions in organic solvents are stable for 1 month at -20°C. We do not recommend storing aqueous solutions for more than one day.
HANDLING: Protect from light.

Product Description
Inhibits aminopeptidases like aminopeptidase B, leucine aminopeptidase, tripeptide aminopeptidase, aminopeptidases on the surface of mammalian cells. Does not inhibit carboxypeptidases. May be used in in vitro translation system to inhibit the aminopeptidases found in reticulocate or wheat germ lysates. Activates macrophages and T lymphocytes. Has antitumor properties and enhances not only blastogenesis and lymphocytes in vitro, but also establishes a delayed-type hypersensitivity in vivo.
Product Specific Literature References
Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes: H. Umezawa, et al.; J. Antibiot. 29, 97 (1976) Abstract
Low-molecular-weight enzyme inhibitors of microbial origin: H. Umezawa; Ann. Rev. Microbiol. 36, 75 (1982) Abstract
Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes: D.H. Rich, et al.; J. Med. Chem. 27, 417 (1984) Abstract
Further Categories Containing This Product:
Antitumor Agents (Enzyme Inhibitors)
 
 
ALX-350-015 Revised 03-Apr-08
(S)-(+)-Camptothecin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Topoisomerase Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-015-M050   50 mg 40.00 USD Add To Cart
ALX-350-015-M250   250 mg 150.00 USD Add To Cart
ALX-350-015-G001   1 g 295.00 USD Add To Cart
Product Specification
FORMULA: C20H16N2O4
MW: 348.4
CAS NUMBER: 7689-03-4
MERCK INDEX: 14: 1735
SOURCE/HOST: Isolated from Mappia foetida Miers (Nothapodytes foetida (Wt.) Sleumer).
PURITY: ≥98% (HPLC)
APPEARANCE: Pale yellow powder.
SOLUBILITY: Soluble in DMSO (10mg/ml), methanol (40mg/ml) or 0.1N sodium hydroxide (50mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HANDLING: Protect from light and moisture. After reconstitution, prepare aliquots and store at -20°C.
HAZARD: IRRITANT. TOXIC.

Product Description
Potent antitumor agent. Inhibitor of DNA-topoisomerase I. Activates p53 resulting in upregulated expression of TRAIL-R2 (DR5) and Bak to overcome TRAIL resistance in Bax-deficient human colon carcinoma cells. Suppresses nitric oxide (NO) biosynthesis.
Product Specific Literature References
M.E. Wall, et al.; JACS 88, 3888 (1966)
The current status of camptothecin analogues as antitumor agents: W.J. Slichenmyer, et al.; J. Natl. Cancer Inst. 85, 271 (1993), (Review) Abstract
RNA synthesis inhibitors increase melatonin production in Y79 human retinoblastoma cells: J.L. Janavs, et al.; Mol. Brain Res. 23, 47 (1994) Abstract
Camptothecins: from bench research to hospital wards: M. Potmesil; Cancer Res. 54, 1431 (1994), (Review) Abstract
Forskolin and camptothecin induce a 30 kDa protein associated with melatonin production in Y79 human retinoblastoma cells: J.L. Janavs, et al.; J. Neurosci. 15, 298 (1995) Abstract
Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives: A. Tanizawa, et al.; Biochemistry 34, 7200 (1995) Abstract
The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription: M. Ljungman & P.C. Hanawalt; Carcinogenesis 17, 31 (1996) Abstract
The cell cycle effects of camptothecin: Z. Darzynkiewicz, et al.; Ann. N. Y. Acad. Sci. 803, 93 (1996) Abstract
Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases: T. Shimizu & Y. Pommier; Leukemia 11, 1238 (1997) Abstract
Camptothecin and taxol: discovery to clinic: M.E. Wall; Med. Res. Rev. 18, 299 (1998), Review Abstract
Camptothecin suppresses nitric oxide biosynthesis in RAW 264.7 macrophages: W.F. Chiou, et al.; Life Sci. 69, 625 (2001) Abstract
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin: D. Chauvier, et al.; J. Pharm. Sci. 91, 1765 (2002) Abstract
Camptothecin and taxol: historic achievements in natural products research: N.H. Oberlies & D.J. Kroll; J. Nat. Prod. 67, 129 (2004), Review Abstract
Camptothecin and its analogues: a review on their chemotherapeutic potential: D. Sriram, et al.; Nat. Prod. Res. 19, 393 (2005), Review Abstract
The effects of camptothecin on RNA polymerase II transcription: roles of DNA topoisomerase I:: G. Capranico, et al.; Biochimie 89, 482 (2007) Abstract
Related Products
Further Categories Containing This Product:
Antitumor Agents (Enzyme Inhibitors) • Natural Products - Nitric Oxide Pathway Modulators • Natural Products - Antitumor Reagents • MDR Inhibitors • p53 Other Products • Alkaloids
 
 
ALX-380-073 Revised 12-Oct-07
Chartreusin
Add to Clipboard
SYNONYMS Lambdamycin
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antitumor Antibiotics
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-073-M005   5 mg 50.00 USD Add To Cart
ALX-380-073-M025   25 mg 200.00 USD Add To Cart
Product Specification
FORMULA: C32H32O14
MW: 640.6
CAS NUMBER: 6377-18-0
MERCK INDEX: 14: 2045
SOURCE/HOST: Isolated from Streptomyces chartreusis.
PURITY: ≥98%
APPEARANCE: Yellow solid.
SOLUBILITY: Soluble in acetone; insoluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HAZARD: TOXIC.
Product Description
Antitumor antibiotic which inhibits topoisomerase II. Induces single-strand scission in DNA in the presence of reducing agents.
Product Specific Literature References
Chartreusin, a New Antibiotic Produced by Streptomyces chartreusis, a New Species: B. E. Leach, et al.; J. Am. Chem. Soc. 75, 4011 (1953)
Chartreusin, a glycosidic antitumour antibiotic from Streptomyces: J.A. Beisler; Prog. Med. Chem. 19, 247 (1982), (Review) Abstract
Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase II: A. Lorico & B.H. Long; Eur. J. Cancer 14, 1985 (1993) Abstract
Chartreusin, elsamicin A and related anti-cancer antibiotics: J. Portugal; Curr. Med. Chem. Anticancer Agents 3, 411 (2003), Review Abstract
Further Categories Containing This Product:
Antitumor Agents (Enzyme Inhibitors) • Antitumor Agents (DNA Interaction & Gene Regulation) • Antibiotics - Topoisomerase Inhibitors
 
 
ALX-270-392 Revised 08-Dec-04
3-(2-Chloro-3-indolylmethylene)-1,3-dihydroindol-2-one
Add to Clipboard
PRODUCT LINE Cell Cycle
PRODUCT CATEGORY CDK & Cyclin Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-392-M001   1 mg 35.00 USD Add To Cart
ALX-270-392-M005   5 mg 130.00 USD Add To Cart
Product Specification
FORMULA: C17H11ClN2O
MW: 294.7
PURITY: ≥95% (HPLC)
APPEARANCE: Yellow to orange solid.
SOLUBILITY: Soluble in DMSO.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: +4°C
USE/STABILITY: Stable for 3 years after receipt when stored at -20°C. Stock solutions are stable for up to 3 months when stored at -20°C.
HANDLING: Packaged under inert gas. After reconstitution, prepare aliquots and store at -20°C. Protect from light.

Product Description
Selective, ATP-competitive inhibitor of CDK1/cyclin B (IC50=5.8µM) and CDK5 (IC50=25µM). Does not inhibit GSK-3β (IC50>100µM). Exhibits potent antiproliferative properties (IC50=2µM in HeLa cells).
Product Specific Literature References
Potential antitumor agents. 25 [1]. Synthesis and cytotoxic activity of 3-(2-chloro-3-indolylmethylene)1,3-dihydroindol-2-ones: A. Andreani, et al.; Anticancer Res. 16, 3585 (1996) Abstract
Imidazo[2,1 -b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK1/cyclin B inhibition: A. Andreani, et al.; Anticancer Drug Des. 15, 447 (2000) Abstract
Further Categories Containing This Product:
Antitumor Agents (Enzyme Inhibitors) • Antitumor Agents (Anti-proliferative)
 
 
ALX-270-089 Revised 25-May-07
D609 . potassium salt
Add to Clipboard
SYNONYMS Tricyclodecan-9-yl xanthogenate . K
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Phospholipase C/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-089-M001   1 mg 25.00 USD Add To Cart
ALX-270-089-M005   5 mg 80.00 USD Add To Cart
Product Specification
FORMULA: C11H15OS2 . K
MW: 227.4 . 39.1
CAS NUMBER: 83373-60-8
PURITY: ≥98%
APPEARANCE: Off-white solid.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
USE/STABILITY: We recommend to prepare fresh solutions each day.

Product Description
Selective inhibitor of phosphatidylcholine-specific phospholipase C. Has been used to study the coupling of phosphatidylcholine-specific phospholipase C with sphingomyelinase. Shows antitumor and antiviral activity. Inhibits basement membrane collagen synthesis, which is the last step in the development of a new blood vessel. Inhibits induction of nitric oxide synthases (NOS). Induces apoptosis.
Product Specific Literature References
DNA and RNA virus species are inhibited by xanthates, a class of antiviral compounds with unique properties: G. Sauer, et al.; PNAS 81, 3263 (1984) Abstract
Interruption of growth signal transduction by an antiviral and antitumoral xanthate compound: K. Muller-Decker, et al.; Exp. Cell. Res. 177, 295 (1988) Abstract
Interruption of TPA-induced signals by an antiviral and antitumoral xanthate compound: inhibition of a phospholipase C-type reaction: K. Muller-Decker; BBRC 162, 198 (1989) Abstract
TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown: S. Schütze, et al.; Cell 71, 765 (1992) Abstract
Inhibitors of basement membrane collagen synthesis prevent endothelial cell alignment in matrigel in vitro and angiogenesis in vivo: G.C. Haralabopoulos, et al.; Lab. Invest. 71, 575 (1994) Abstract
Induction of nitric oxide synthase activity in phagocytic cells inhibited by tricyclodecan-9-yl-xanthogenate (D609): K. Tschaikowsky, et al.; Br. J. Pharmacol. 113, 664 (1994) Abstract
Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis: D.C. Hooper, et al.; PNAS 94, 2528 (1997) Abstract; Full Text
The antiviral xanthate compound D609 inhibits herpes simplex virus type 1 replication and protein phosphorylation: D.G. Walro & K.S. Rosenthal; Antiviral. Res. 36, 63 (1997) Abstract
Induction of apoptosis and potentiation of TNF- and Fas-mediated apoptosis in U937 cells by the xanthogenate compound D609: M.I. Porn-Ares, et al.; Exp. Cell Res. 235, 48 (1997) Abstract
Phosphatidylcholine-specific phospholipase inhibitor D609 differentially affects MAP kinases and immediate-early genes in PC12 cells: P.J. Kahle, et al.; Cell Signal. 10, 321 (1998) Abstract
Stimulation of DNA synthesis in untransformed cells by the antiviral and antitumoral compound tricyclodecan-9-yl-xanthogenate (D609): Z. Kiss, et al.; Biochem. Pharmacol. 55, 915 (1998) Abstract
A phosphatidylcholine phospholipase C inhibitor, D609, blocks interleukin-3 (IL-3)-induced bcl-2 expression but not c-myc expression in human IL-3-dependent cells: R.A. Mufson, et al.; Exp. Cell Res. 240, 228 (1998) Abstract
D609-phosphatidylcholine-specific phospholipase C inhibitor attenuates thapsigargin-induced sodium influx in human lymphocytes: J.R. Nofer, et al.; Cell Signal. 12, 289 (2000)